Compare NATR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | ELDN |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.9M | 291.8M |
| IPO Year | 1995 | 2014 |
| Metric | NATR | ELDN |
|---|---|---|
| Price | $14.19 | $62.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $28.33 | $8.50 |
| AVG Volume (30 Days) | 200.6K | ★ 941.4K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | 30.67 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $480,144,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $29.79 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $12.97 | $1.35 |
| 52 Week High | $28.14 | $4.60 |
| Indicator | NATR | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 19.81 | 43.30 |
| Support Level | N/A | $3.31 |
| Resistance Level | $21.36 | $4.21 |
| Average True Range (ATR) | 0.65 | 0.17 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 0.62 | 32.52 |
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.